CARFILZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA

被引：4
作者：
Lue, J. [1 ]
Goel, S. [1 ]
Mazumder, A. [1 ]
机构：
[1] NYU, Langone Med Ctr, New York, NY 10016 USA
来源：
DRUGS OF TODAY | 2013年 / 49卷 / 03期
关键词：
Carfilzomib; Proteasome inhibitor; Multiple myeloma; SINGLE-AGENT CARFILZOMIB; PROTEASOME INHIBITOR CARFILZOMIB; IRREVERSIBLE INHIBITOR; COMBINATION THERAPY; DOSE DEXAMETHASONE; OPEN-LABEL; BORTEZOMIB; PHARMACOKINETICS; PR-171; LENALIDOMIDE;
D O I：
10.1358/dot.2013.49.3.1939264
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Carfilzomib is a second-generation selective proteasome inhibitor that has been recently approved in the use for refractory multiple myeloma. It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib. Recent and ongoing clinical trials are establishing the role of carfilzomib in the treatment of refractory multiple myeloma.
引用
收藏
页码：171 / 179
页数：9
相关论文
共 26 条
  • [1] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
    Alsina, Melissa
    Trudel, Suzanne
    Furman, Richard R.
    Rosen, Peter J.
    O'Connor, Owen A.
    Comenzo, Raymond L.
    Wong, Alvin
    Kunkel, Lori A.
    Molineaux, Christopher J.
    Goy, Andre
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4830 - 4840
  • [2] American Cancer Society, 2012, Cancer Facts and Figures 2012
  • [3] [Anonymous], ASH ANN M
  • [4] [Anonymous], 2011, BLOOD, DOI DOI 10.1182/BLOOD.V118.21.2930.2930
  • [5] Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
    Arastu-Kapur, Shirin
    Anderl, Janet L.
    Kraus, Marianne
    Parlati, Francesco
    Shenk, Kevin D.
    Lee, Susan J.
    Muchamuel, Tony
    Bennett, Mark K.
    Driessen, Christoph
    Ball, Andrew J.
    Kirk, Christopher J.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2734 - 2743
  • [6] Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency
    Badros, A. Z.
    Vij, R.
    Martin, T.
    Zonder, J. A.
    Wong, A. F.
    Woo, T.
    Boussina, K.
    Wang, Z.
    Niesvizky, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice
    Bruna, Jordi
    Udina, Esther
    Ale, Albert
    Vilches, Jorge J.
    Vynckier, Ann
    Monbaliu, Johan
    Silverman, Lee
    Navarro, Xavier
    [J]. EXPERIMENTAL NEUROLOGY, 2010, 223 (02) : 599 - 608
  • [8] Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
    Demo, Susan D.
    Kirk, Christopher J.
    Aujay, Monette A.
    Buchholz, Tonia J.
    Dajee, Maya
    Ho, Mark N.
    Jiang, Jing
    Laidig, Guy J.
    Lewis, Evan R.
    Parlati, Francesco
    Shenk, Kevin D.
    Smyth, Mark S.
    Sun, Congcong M.
    Vallone, Marcy K.
    Woo, Tina M.
    Molineaux, Christopher J.
    Bennett, Mark K.
    [J]. CANCER RESEARCH, 2007, 67 (13) : 6383 - 6391
  • [9] Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (25) : 2645 - 2654
  • [10] An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
    Jagannath, Sundar
    Vij, Ravi
    Stewart, A. Keith
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Reiman, Tony
    Somlo, George
    Bahlis, Nizar
    Lonial, Sagar
    Kunkel, Lori A.
    Wong, Alvin
    Orlowski, Robert Z.
    Siegel, David S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05) : 310 - 318
123